2025 Dinner Short Courses* (In-Person Only)

Short courses at Drug Discovery Chemistry are designed to be instructional, interactive, and provide in-depth information on a specific topic with opportunities for Q&A throughout. The courses include introductions for those new to the fields and those looking to learn more, as well as explanations on more technical aspects than time allows during our main conference presentations. Instructors are drawn from industry and academics alike, and many are recognized authorities in the fields or have teaching experience.

Dinner short courses will take place on Monday evening, April 14 and Wednesday evening, April 16 and be offered IN-PERSON ONLY.

*Premium Pricing or separate registration required


Monday, April 14, 2025  6:00 - 8:30 pm

SC1: Protein Degraders: A Beyond Rule of Five Space and in vitro ADME Perspective

This course focuses on proteolysis targeting chimeras (PROTACs) and will cover topics relevant to developing them as oral therapeutics. Topics to be covered in this part of the course will include their physicochemical properties and how these influence solubility and permeability and assays to determine polarity. We will also examine ADME topics focusing on in vitro assays including stability assays, transporters, drug-drug interactions (DDIs), Cytochrome P450 (CYP450) inhibition, etc.
John Erve, PhD, President, Jerve Scientific Consulting
Stefanus Steyn, PhD, Research Fellow, Pharmacokinetics Dynamics & Metabolism, Pfizer

Instructors:

John Erve, PhD, President, Jerve Scientific Consulting

Stefanus Steyn, PhD, Research Fellow, Pharmacokinetics Dynamics & Metabolism, Pfizer


Topics to be Covered:

  • Comparison of Rule of Five and Beyond Rule of Five space
  • Importance of intramolecular hydrogen bonds for solubility and permeability
  • Determining chameleonicity and its importance for PROTACs
  • Transporters and potential drug-drug interactions (DDIs)​

Who Should Attend:

Scientists in the field of proteolysis-targeting chimeras (PROTACs) who would like to deepen their understanding of these molecules and the physicochemical attributes that may contribute to their success as oral drugs. ADME scientists and medicinal chemists wishing to understand PROTACs from a drug safety and metabolism perspective. Graduate students and academic scientists interested in learning more about this rapidly developing new drug modality.

INSTRUCTOR BIOGRAPHIES:

John Erve, PhD, President, Jerve Scientific Consulting

John Erve is from Chicago and studied Chemistry (BS, MS) at the University of Chicago and earned a PhD in Toxicology at Oregon State University. Following postdoctoral work at Vanderbilt (1995-1999) he joined BD-Biosciences (Woburn, MA) as a Study Director. In 2002, he joined AstraZeneca (Sweden) where he characterized reactive metabolites. In 2004 he joined Wyeth (Collegeville, PA) as a Principal Scientist responsible for metabolite identification. In 2010, John joined Novartis (Cambridge, MA) as a Lab Head in Analytical Sciences. John returned to drug metabolism at Elan Pharmaceuticals (San Francisco, CA) in 2012 and later formed Jerve Scientific Consulting, Inc to help small biotech companies in the Bay area with their drug discovery efforts. John was a certified D.A.B.T. from 2004 to 2019.

Stefanus Steyn, PhD, Research Fellow, Pharmacokinetics Dynamics & Metabolism, Pfizer

I have a Ph.D. in Pharmaceutical Chemistry and completed post-doctoral studies in the laboratory of Professor Neal Castagnoli at Virginia Tech. I have over 20 years pharmaceutical industry experience with over forty co-authored publications. I have spent most of my career at Pfizer in various roles within PDM (DMPK), supporting projects ranging from oncology to neuroscience and currently, Inflammation and Immunology (I&I). I am currently a Research Fellow, and my responsibilities include setting the DMPK research and project strategies within the I&I Research Unit. In addition, my team and I function as Project Representative within I&I while I also have responsibilities as a Research Project Lead for various Discovery programs. My interests include prediction of human ADME as well as exploring physicochemical properties and how they relate to ADME with a focus on absorption. PROTACs are of special interest given their unique beyond Rule-of-5 properties and the ADME challenges they present relative to classical small molecules.

 

SC2: Fragment-Based Drug Design: Advancing Tools and Technologies

This course aims to introduce the fundamentals of Fragment-Based Lead Discovery (FBLD) to attendees. The first section will focus on the concepts of using fragments for hit generation. Special emphasis will be placed on practical pitfalls and the many ways to advance fragments to leads and drugs. The second part of the course will discuss the variety of fragment screening methods and when they are best applied. The composition of fragment libraries will also be discussed in detail. The attendees should come away from this course with a solid understanding of what FBLD is and how to apply it.
Ben J. Davis, PhD, Research Fellow, Biology, Vernalis R&D Ltd.
Daniel A. Erlanson, PhD, Chief Innovation Officer, Frontier Medicines Corporation

Instructors:

Ben J. Davis, PhD, Research Fellow, Biology, Vernalis R&D Ltd.

Daniel A. Erlanson, PhD, Chief Innovation Officer, Frontier Medicines Corporation


Topics to be Covered:

  • Pros and cons of fragment-based approaches 
  • What makes a good fragment; properties of a good fragment library 
  • Finding, validating, and characterizing low-affinity ligands 
  • The importance of using orthogonal screening methods
  • What to do with a fragment—growing, linking, and more​

INSTRUCTOR BIOGRAPHIES:

Ben J. Davis, PhD, Research Fellow, Biology, Vernalis R&D Ltd.

Dr. Ben Davis is a Research Fellow at Vernalis Research, a biotech company based in Cambridge UK which has been at the forefront of fragment-based approaches since 1998. An NMR spectroscopist and biophysicist by training, his current research focus is the development of biophysics and FBLD methods for challenging therapeutic targets and systems. Dr Davis studied for his PhD in protein folding and molecular interactions with Professor Alan Fersht at Cambridge University, and then studied the interactions of small molecules with proteins and RNA. He has over 20 years’ experience in the drug discovery industry. He has contributed to seven books over the last decade and is an author on more than forty scientific publications. He is a frequent speaker at scientific conferences and has been running FBLD training workshops since 2007.

Daniel A. Erlanson, PhD, Chief Innovation Officer, Frontier Medicines Corporation

Dr. Daniel A. Erlanson is the Chief Innovation Officer for Frontier Medicines, which is using covalent fragments, machine learning, and chemoproteomics to target proteins often thought undruggable. Prior to Frontier he co-founded Carmot Therapeutics, where he contributed to two clinical-stage molecules. Before Carmot, Dr. Erlanson spent a decade developing fragment-based discovery technologies and leading medicinal chemistry projects at Sunesis Pharmaceuticals. Dr. Erlanson was an NIH postdoctoral fellow with James A. Wells at Genentech, earned his PhD in chemistry from Harvard University in the laboratory of Gregory L. Verdine, and his BA in chemistry from Carleton College. He has co-edited two books on fragment-based drug discovery and is an inventor on more than a dozen issued patents and an author of more than forty scientific publications. He also runs a blog devoted to fragment-based drug discovery, Practical Fragments (http://practicalfragments.blogspot.com/).

 

SC3: Fundamentals of Generative AI for Drug Discovery

Deep generative modeling is rapidly transforming de novo drug discovery, streamlining the entire process. This course aims to explain the potential of AI, machine learning, and generative AI models in creating tailored molecules with specific properties. It explores the fundamentals of Variational Autoencoders, Generative Adversarial Networks, Transformers, Large Language Models (LLMs), BERT, and GPT models in the context of drug discovery, highlighting their crucial role in reshaping the pharmaceutical landscape. Along the way, we'll dissect three pivotal techniques for biopharma specific LLMs: prompt engineering, retrieval augmented generation (RAG), and fine-tuning. This course is designed for medicinal chemists, molecular modeling users, and project managers seeking to harness the capabilities of modern Generative AI concepts and integrate them into their work.
Parthiban Srinivasan, PhD, Professor and Director, Centre for AI in Medicine, Vinayaka Mission's Research Foundation, India
Petrina Kamya, PhD, Global Head of AI Platforms & Vice President, Insilico Medicine; President, Insilico Medicine Canada

Instructors:

Parthiban Srinivasan, PhD, Professor and Director, Centre for AI in Medicine, Vinayaka Mission's Research Foundation, India

Petrina Kamya, PhD, Global Head of AI Platforms & Vice President, Insilico Medicine; President, Insilico Medicine Canada


Topics to be Covered:    

  • Demystifying generative AI concepts and key terminologies  
  • How predictive and generative AI works in de novo molecular design
  • Overview of large language models (LLMs)  
  • Prompt engineering, RAG, and fine-tuning for biopharma-specific LLMs
  • Leveraging language models in drug discovery research with case studies​​

Who Should Attend:

This course is designed for medicinal chemists, molecular modeling users, and project managers seeking to harness the capabilities of modern generative AI concepts and integrate them into their work.

INSTRUCTOR BIOGRAPHIES:

Parthiban Srinivasan, PhD, Professor and Director, Centre for AI in Medicine, Vinayaka Mission's Research Foundation, India

Parthiban Srinivasan, an experienced data scientist, earned his PhD from Indian Institute of Science, specializing in Computational Chemistry. After his PhD, he continued the research at NASA Ames Research Center (USA) and Weizmann Institute of Science (Israel). Then he worked at AstraZeneca in the area of Computer Aided Drug Design for Tuberculosis. Later, he headed informatics business units in Jubilant Biosys and then in GvkBio before he floated the company, Parthys Reverse Informatics and later an AI consultancy, Vingyani. Then he returned to academia as a Professor of Data Science at the Indian Institute of Science Education and Research, Bhopal. Currently, Parthiban is a Professor and Director at the Center for AI in Medicine, Vinayaka Missions Research Foundation, AV Medical College and Hospital, Puducherry, India

Petrina Kamya, PhD, Global Head of AI Platforms & Vice President, Insilico Medicine; President, Insilico Medicine Canada

Petrina Kamya, PhD, is the Head of AI Platforms and President of Insilico Medicine, Canada an end-to-end artificial intelligence-driven drug discovery company. Before joining Insilico, Dr. Kamya spent eight years in various roles at Chemical Computing Group that involved scientific and business-related aspects of preclinical drug discovery. In addition to establishing the corporate strategy for the sales and business development of molecular modeling software for academia, she also played an active role as an application scientist working on real-world discovery projects and finally in a senior role in strategy and business development for pharma and biotech companies. Following her time at CCG, Petrina moved to Certara as a Market Access Manager, where she learned first-hand the challenges of getting drugs to market. Petrina has been with Insilico Medicine since August 2020. She holds a PhD in Chemistry (specializing in computational chemistry) from Concordia University.

 

SC4: Detecting Target Engagement: Technology Innovations

This course covers a range of biochemical or biophysical tools adapted to gauge interaction between a compound of interest (either a tool compound or potential therapeutic) with its intended disease-related molecular target. Most of the applications are employed at the hit-confirmation steps in the drug lead generation process, to discover small molecule compounds that engage difficult-to-drug protein targets. Applications to primary screening steps may also be covered.
Hans-Peter N. Biemann, PhD, Distinguished Scientist, Integrated Drug Discovery, Sanofi
Jonathan Brooks, Principal Scientist, Inflammation & Remodeling, Pfizer Inc.
Can Ozbal, PhD, CEO, Momentum Biotechnologies
Elmar Nurmemmedov, PhD, MBA, Co-Founder & CEO, CellarisBio

Instructors:

Hans-Peter N. Biemann, PhD, Distinguished Scientist, Integrated Drug Discovery, Sanofi

Jonathan Brooks, Principal Scientist, Inflammation & Remodeling, Pfizer Inc.

Can Ozbal, PhD, CEO, Momentum Biotechnologies

Elmar Nurmemmedov, PhD, MBA, Co-Founder & CEO, CellarisBio

 

 


Topics to be Covered:

(1) Fluorescence Resonance Energy Transfer (FRET) & Cellular Target Engagement by Elmar Nurmemmedov, CellarisBio

  • Why measuring cellular target engagement early in drug discovery is important for challenging drug targets
  • Pros and cons of fluorescence-based Micro-Tag cellular target engagement methods and comparison to other cell target engagement methods
  • Case studies and novel applications of fluorescence-based Micro-Tag cellular target engagement method

(2) Affinity Selection Mass Spectrometry (ASMS) by Hans Biemann, Sanofi and Can Ozbal, Momentum Bio

  • Overview of ASMS as a biophysical assay technique
  • ASMS for highthroughput screening
  • ASMS for compound binding studies
  • Sanofi case studies

(3) SPR Microscopy for Membrane Proteins by Jonathan Brooks, Pfizer​​

  • ​Introduction to SPRm and ligand tracer platforms
  • Examples of SPRm applied to cell binding kinetics
  • Cell attachment strategies for SPRm
  • Working with live and fixed cells
  • Binding of large v. small molecules

INSTRUCTOR BIOGRAPHIES:

Hans-Peter N. Biemann, PhD, Distinguished Scientist, Integrated Drug Discovery, Sanofi

Hans-Peter Biemann has originated innovative discovery programs and applied emerging small molecule technologies during tenures in Genzyme’s and Sanofi’s Drug Discovery units. Contributions on preclinical and clinical agents have included partnerships with academic leaders and start-ups. Working across various disciplines (protein biochemistry, cell biology, structural biology, biophysics), Hans has conducted and led phenotypic, fragment-based, and HTS-based drug discovery. He established productive FBDD, high-res Cryo EM drug design, Affinity Selection Mass Spectrometry over the past 15 years at Sanofi/Genzyme. Prior to joining Genzyme in the 1990s, he completed a post doc in Daniel Koshland’s U.C. Berkeley group and trained in Raymond Erikson’s Harvard group (PhD). His B.S. was earned at Yale.

Jonathan Brooks, Principal Scientist, Inflammation & Remodeling, Pfizer Inc.

Jonathan began his career at Genetics Institute in 1990 developing immunoassays for use in pharmacokinetics and process development. Jon has over 30 years of experience in label free analysis of receptor ligand interactions and small molecule target binding associated with several respiratory and inflammatory disease areas. Currently, he is a principal scientist in the inflammation and Immunology drug discovery research unit at Pfizer in Cambridge Massachusetts. His current focus is on-cell target interaction analysis using SPRm. Jon received his MS in Biology from Harvard University.

Can Ozbal, PhD, CEO, Momentum Biotechnologies

Growing up in Istanbul Dr. Ozbal came to the United States for his advanced studies where he received an AB in Chemistry from Bowdoin College and a PhD in Toxicology (now part of the Biological Engineering) from MIT. After a brief academic career, he joined BioTrove as the first employee where he was part of the team that developed and commercialized the RapidFire high-throughput mass spectrometry platform. Upon the sale of BioTrove to Life Technologies in 2009, Dr. Ozbal was part of the team that spun out the RapidFire business as a separate company called Biocius Life Sciences where he was the Chief Operating Officer. Biocius was acquired by Agilent Technologies in 2011 where he stayed on for 2.5 years as a senior manager and led teams focused on early drug discovery applications. In 2014, Dr. Ozbal left Agilent to launch and lead PureHoney Technologies, a contract research organization specializing in mass spectrometry-based bioanalysis with a focus on drug discovery. In 2023, PureHoney was acquired by Care Equity and rebranded as Momentum Biotechnologies where he continues to serve as CEO.

Elmar Nurmemmedov, PhD, MBA, Co-Founder & CEO, CellarisBio

Elmar Nurmemmedov is a scientist in the field of drug discovery. PhD in molecular biophysics from Lund University, Sweden. Postdoctoral training from Harvard Medical School and Scripps Research Institute. Cofounder and CEO of CellarisBio.

Wednesday, April 16, 2025  6:15 - 8:45 pm

SC5: Protein Degraders: An in vivo ADME and Safety Perspective

This course focuses on proteolysis targeting chimeras (PROTACs) and will cover topics relevant to developing them as therapeutics. Topics to be covered in this part of the course will include looking at what is known about how PROTACs are metabolized in vivo and strategies to deliver them with adequate PK/PD. The unique mechanism of action of PROTACs gives rise to some drug safety issues not seen in small molecules, which will be discussed. Finally, we will explore the possible relevance of circadian rhythm to protein degradation and PROTACs.
Bin Ma, PhD, Sr Principal Scientist, Drug Metabolism & Pharmacokinetics, Genentech Inc
John Erve, PhD, President, Jerve Scientific Consulting

Instructors:

Bin Ma, PhD, Sr Principal Scientist, Drug Metabolism & Pharmacokinetics, Genentech Inc

John Erve, PhD, President, Jerve Scientific Consulting


Topics to be Covered:

  • Measuring ADME properties in vitro and in vivo and specific challenges
  • Metabolism of PROTACs and influence of linker length on stability
  • Case study of optimizing a PROTAC
  • Safety issues unique to PROTACs
  • Circadian rhythm considerations​

Who Should Attend:

Scientists in the field of proteolysis targeting chimeras (PROTACs) and would like to deepen their understanding of these molecules and the physicochemical attributes that may contribute to their success as oral drugs. ADME scientists and medicinal chemists wishing to understand PROTACs from a drug safety and metabolism perspective. Graduate students and academic scientists interested in learning more about this rapidly developing new drug modality.

INSTRUCTOR BIOGRAPHIES:

Bin Ma, PhD, Sr Principal Scientist, Drug Metabolism & Pharmacokinetics, Genentech Inc

Dr. Bin Ma is a Senior Principal Scientist in the DMPK department at Genentech, focusing on the metabolism of novel drug modalities including macrocyclic peptides, disulfide constrained peptides, protein degraders, and oligonucleotides. He earned his PhD in Pharmacology from The Chinese University of Hong Kong and completed postdoctoral research at the University of Minnesota. Before joining Genentech, he worked as a Staff Scientist at the Masonic Cancer Research Center and later at Gilead Sciences. Dr. Ma’s research has been featured as cover stories in several scientific journals, including J. Med. Chem., Carcinogenesis, Mutagenesis, and Chem. Res. Toxicol.

John Erve, PhD, President, Jerve Scientific Consulting

John Erve is from Chicago and studied Chemistry (BS, MS) at the University of Chicago and earned a PhD in Toxicology at Oregon State University. Following postdoctoral work at Vanderbilt (1995-1999) he joined BD-Biosciences (Woburn, MA) as a Study Director. In 2002, he joined AstraZeneca (Sweden) where he characterized reactive metabolites. In 2004 he joined Wyeth (Collegeville, PA) as a Principal Scientist responsible for metabolite identification. In 2010, John joined Novartis (Cambridge, MA) as a Lab Head in Analytical Sciences. John returned to drug metabolism at Elan Pharmaceuticals (San Francisco, CA) in 2012 and later formed Jerve Scientific Consulting, Inc to help small biotech companies in the Bay area with their drug discovery efforts. John was a certified D.A.B.T. from 2004 to 2019.

 

SC6: Chemical Biology for Covalent Drug Discovery, Phenotypic Screening, and Target Deconvolution

This course is designed to provide an overview and best practices in the use of chemical biology probes and assays that have been developed for applications in early drug discovery. Chemists and biologists working in lead generation, assay development, phenotypic screening, target discovery and deconvolution, target engagement and mechanism-of-action (MoA) studies will all benefit from attending this course. The instructors will share their knowledge and expertise around the use of various technologies and chemistries, and there will be time for open discussion and exchange of ideas.
Paul Brennan, PhD, Professor, Nuffield Department of Medicine, University of Oxford
Jarrett R. Remsberg, PhD, Senior Scientist I, Platform and Proteomics, Belharra Therapeutics
Angelo Andres, Senior Scientist, Chemical Biology, AstraZeneca

Instructors:

Paul Brennan, PhD, Professor, Nuffield Department of Medicine, University of Oxford

Jarrett R. Remsberg, PhD, Senior Scientist I, Platform and Proteomics, Belharra Therapeutics

Chemical Biology Tools for Target Deconvolution: Probes and Constructs for Target Engagement and Mechanistic Understanding

Angelo Andres, Senior Scientist, Chemical Biology, AstraZeneca


Topics to be Covered:

  • Chemical biology assays and probes for target engagement and mechanistic understanding
  • Chemoproteomic methods and reagents for covalent ligand drug discovery
  • Comparison of various chemical biology approaches (mass spectrometry, affinity-bead methods, proximity labeling proteomics, and more) 
  • Use of quantitative mass spectrometry-based proteomics and global proteomics
  • Discovery of chemical probes 
  • Constructing annotated chemogenomic compound sets for phenotypic screening
  • Cysteine profiling and covalent inhibitors for target discovery and occupancy
  • Design and screening of chemogenomics libraries for target identification
  • Case studies highlighting use of proteomics for target engagement and deconvolution​​​​

INSTRUCTOR BIOGRAPHIES:

Paul Brennan, PhD, Professor, Nuffield Department of Medicine, University of Oxford

Paul Brennan received his PhD in organic chemistry from UC Berkeley. Following post-doctoral research at Cambridge University, Paul spent eight years working in the pharmaceutical industry at Amgen and Pfizer. After leaving Pfizer in 2011, Paul joined the Structural Genomics Consortium at the University of Oxford and led the chemical probes discovery effort on epigenetic targets. After leaving the SGC in 2019, Paul was Head of Chemistry and then Chief Scientific Officer of the Alzheimer’s Research UK Oxford Drug Discovery Institute where his research was focused on finding new treatments for dementia. In addition to dementia, over the course of his career, Paul has worked on discovering new medicines for cancer, incontinence, pain, rare diseases, and inflammation. Paul is currently Professor of Medicinal Chemistry and Director of the Centre for Medicines Discovery at the University of Oxford and a scientific advisor to the biotech and pharmaceutical industries. His research centre is focused on early medicines discovery for poorly treated diseases.

Jarrett R. Remsberg, PhD, Senior Scientist I, Platform and Proteomics, Belharra Therapeutics

Jarrett Remsberg first trained at the National Cancer Institute developing peptide-based inhibitors of membrane signaling pathways. He earned a BS in both Chemical-Biological Engineering and Biology from MIT and his PhD in Biochemistry and Molecular Biophysics at the University of Pennsylvania Perelman School of Medicine with Professor Mitch Lazar. Jarrett then joined the Cravatt Lab at Scripps Research for postdoctoral studies as an American Cancer Society Fellow. His research focused on applying chemoproteomic techniques to interrogate the ligandable proteome, including serine hydrolases involved in NRAS depalmitoylation and function-first strategies to assess the global impact of electrophilic compounds on protein complexes in human cells. Jarrett has since moved to industry as one of the first employees to join Belharra Therapeutics, establishing a novel photoaffinity-based chemoproteomic platform and continuing to advance mass spectrometry and chemoproteomic techniques to accelerate drug discovery.

Angelo Andres, Senior Scientist, Chemical Biology, AstraZeneca

Angelo Andres is a Senior Scientist within the Chemical Biology & Proteomics group at AstraZeneca. Before embarking on his scientific journey he served in the GWOT with the U.S. Army. He then earned a PhD in Medicinal Chemistry from The University of Kansas where he specialized in the development of cellular probes and assays to study live cell target engagement by small molecules. At AstraZeneca he collaborates across functions to develop lysosomal degradation modalities, generate synthetic probes to facilitate lead generation, and applies proteomics to support drug discovery programs across multiple therapeutic modalities spanning small molecules, degraders, and cell therapies.

 

SC7: AI Applications in Drug Development: Strategies for Innovation and Integration

This course is intended to facilitate harnessing the transformative potential of artificial intelligence (AI) in pharmaceutical R&D. Through engagement with real-world case studies, we intend to collaboratively gain insights into state-of-the-art technologies and develop strategies to effectively integrate AI into pharma R&D processes. This course is intended to equip the attendee with the knowledge to optimize their R&D pipeline, enhance strategic decision-making, and position their organization at the forefront of AI-driven innovation in pharmaceuticals.
Arvind Rao, PhD, Associate Professor, Department of Computational Medicine and Bioinformatics, University of Michigan

Instructor:

Arvind Rao, PhD, Associate Professor, Department of Computational Medicine and Bioinformatics, University of Michigan


Topics to be Covered: 

  • AI applications in target discovery and predictive diagnostics 
  • Machine learning strategies for patient stratification and personalized medicine 
  • Frameworks for scaling AI initiatives across pharmaceutical organizations
  • Critical considerations for implementing and managing AI projects 
  • Ethical implications and emerging trends in AI-driven drug development

Who Should Attend:

Designed for scientific directors, business development executives, and project managers, this program provides advanced insights and practical knowledge to drive innovation and foster effective collaboration between AI specialists and traditional R&D teams.​

INSTRUCTOR BIOGRAPHIES:

Arvind Rao, PhD, Associate Professor, Department of Computational Medicine and Bioinformatics, University of Michigan

Arvind Rao is an Associate Professor in the Department of Computational Medicine and Bioinformatics at the University of Michigan. His group uses image analysis and machine learning methods to link image-derived phenotypes with genetic data, across biological scale (i.e. single cell, tissue and radiology data). Such methods have found application in radiogenomics and drug repurposing based on phenotypic screens. Arvind received his PhD in Electrical Engineering and Bioinformatics from the University of Michigan, specializing in transcriptional genomics, and was a Lane Postdoctoral Fellow at Carnegie Mellon University, specializing in bioimage informatics.

 

SC8: Principles of Drug Design: Ligand-Receptor Interactions and More

This course provides an overview of protein-ligand interactions and drug design principles. The presentation is targeted to medicinal chemists. The course starts by covering hydrophobic, H-bonding and electrostatic interactions. Then the course moves into coverage of specialized topics such as conformation analysis, pi-stack, cation-pi, halogen bonding, protein-protein interface, and covalent inhibition. Medicinal chemistry case studies are incorporated.
Maricel Torrent, PhD, Principal Research Scientist, Computational Drug Discovery, AbbVie, Inc.

Instructor: 

Maricel Torrent, PhD, Principal Research Scientist, Computational Drug Discovery, AbbVie, Inc.


Topics to be Covered:

  • Medicinal chemistry and structure-based drug design principles
  • Interpretation of atomic-level protein X-ray and modeled structures of binding mode
  • Understanding the relative amounts of potency gain from different types of interactions
  • Case studies to illustrate all the design strategies​

INSTRUCTOR BIOGRAPHIES:

Maricel Torrent, PhD, Principal Research Scientist, Computational Drug Discovery, AbbVie, Inc.

Result-oriented Computational Chemist with more than two decades of pharma industry experience in the application of Molecular Modeling to small molecule drug discovery. Key player in global pharmaceutical companies, Merck, Abbott, AbbVie. Technical skills and scientific strengths include 3D- and 2D-, ligand-based and structure-based drug design, as well as data mining and analysis. Strong competence as a team player, team builder, mentor, and group leader. Excels at creatively solving challenging problems that require tenacity and drive, and that involve multiple experts. Co-author of more than 90 peer-reviewed scientific articles and patents; two book chapters.

 

SC9: DNA-Encoded Libraries

This course provides an overview of DNA-Encoded Library (DEL) screening platforms, discusses common selection strategies for identifying novel hits from DEL campaigns and delves into parameters for building a library collection. The instructors will also cover strategic considerations in using DEL selection data to accelerate hit-to-lead steps in drug discovery.
Svetlana Belyanskaya, PhD, Co-Founder, DEL Source; Former DEL Platform Manager; GSK; Vice President, Biology, Anagenex
Ghotas Evindar, PhD, Co-Founder & President, DEL Source; Former DEL Platform Senior Manager, GSK, and Head of Research at Exo Therapeutics

Instructors:

Svetlana Belyanskaya, PhD, Co-Founder, DEL Source; Former DEL Platform Manager; GSK; Vice President, Biology, Anagenex

Ghotas Evindar, PhD, Co-Founder & President, DEL Source; Former DEL Platform Senior Manager, GSK, and Head of Research at Exo Therapeutics


Topics to be Covered:

  • Introduction to DNA-encoded libraries
  • Pros and cons of using DNA-encoded chemical libraries
  • Structure of the DNA coding region and how it has evolved over time
  • Affinity-based selection strategy and how it guides hit-picking
  • Data analysis and the decision-making logic in hit confirmation
  • Introduction to and benefits of one-bead, one-compound (OBOC) DNA-encoded libraries​

INSTRUCTOR BIOGRAPHIES:

Svetlana Belyanskaya, PhD, Co-Founder, DEL Source; Former DEL Platform Manager; GSK; Vice President, Biology, Anagenex

Dr. Svetlana Belyanskaya is an expert in small molecule drug discovery and a globally recognized leader in DNA-Encoded Library (DEL) technology. With over two decades of hands-on experience, she played a key role in the discovery of the first DEL-derived compound to advance into clinical trials—a landmark achievement that helped validate the platform’s potential. Dr. Belyanskaya has been at the forefront of DEL innovation since its inception, driving platform development and hit discovery strategies at pioneering organizations such as Praecis Pharmaceuticals, GlaxoSmithKline (GSK), and Anagenex Inc. Her work integrates deep expertise in DEL screening, assay design, and early-stage drug development, bringing together scientific precision and strategic insight. A passionate advocate for the DEL community, she is a frequent speaker at international conferences, the author of numerous publications, and an instructor of specialized courses on DEL applications in modern drug discovery. She also serves as a strategic advisor to emerging biotech companies leveraging DEL technologies. Dr. Belyanskaya previously held senior scientific leadership roles at GSK and served as Vice President of Biology at Anagenex. She is currently the co-founder and executive leader at DEL Source Inc., where she continues to advance the field and shape the future of drug discovery. (LinkedIn).

Ghotas Evindar, PhD, Co-Founder & President, DEL Source; Former DEL Platform Senior Manager, GSK, and Head of Research at Exo Therapeutics

Dr. Ghotas Evindar is a recognized leader in drug discovery and a pioneer in DNA-Encoded Library (DEL) technology. As Co-Founder and President of DEL Source Inc., he brings over two decades of experience in advancing small-molecule therapeutics across the biotech and pharmaceutical industries. Born in the Kurdish mountains and educated in Canada, Dr. Evindar earned his BSc and MSc in biochemistry and bio-organic chemistry from the University of Waterloo, followed by a PhD in organic chemistry from the University of Toronto. He began his industrial career as a medicinal chemist at Vertex Pharmaceuticals, where he focused on structure-based drug design. Dr. Evindar was a core member of the original team at Praecis Pharmaceuticals that pioneered the DEL platform and helped shape it into a transformative drug discovery technology. He later led the DEL discovery efforts at GlaxoSmithKline (GSK), where he served as Senior Site Manager in Boston for 15 years. Prior to founding DEL Source, Dr. Evindar held executive leadership roles as Head of Drug Discovery at both 1859 Inc. and Exo Therapeutics. Across his career, he has led multiple discovery programs from early hits to development candidates, authored more than 50 publications and patents, and served as a strategic advisor to numerous biotech and pharmaceutical companies. A passionate advocate for the DEL platform, Dr. Evindar is also an active educator and speaker, regularly leading industry courses, panels, and workshops to support the adoption and advancement of DEL technologies in modern drug discovery.